joint corp buy pt increas pt growth opportun franchis compani
clinic improv profit analyst anthoni vendetti full summari
inc buy pt expect competitor buy draa player tri catch lead
cloud data servic rais pt analyst nehal chokshi full summari
lassa fever mer analyst jason mccarthi ph full summari
corpor event call maxim salesperson inform
reed inc reed cover vendetti ndr san francisco ceo val stalowir mon apr
inc cover confer call presid scott colosi senior director
ir/financi report tonya robinson mon may
inc cover confer call cfo kate jaspon presid david
cover ndr boston cfo golder wed jun
corpor ctrl cover chokshi ndr boston ct nyc cfo mark novakovich mon-w
annual silicon valley bu tour host chokshi tue juli
profir energi inc pfie host jang ndr nyc ceo brendan hatch cfo ryan oviatt wed thur
tecogen inc tgen cover jang institut group dinner nyc boston ceo benjamin lock
head tgen ultera emiss technolog robert panora wed apr
increas pt growth opportun
franchis compani clinic improv profit
expect expans region develop program drive franchis
clinic growth well improv oper result clinic level
also see signific revenu growth opportun compani resum
open purchas clinic corporate-own portfolio
expect prudent ad corporate-own clinic strateg
locat method pace help compani avoid drag
profit caus previou manag rapid expans effort
due signific growth opportun improv profit
confid manag believ risk project
decreas therefor lower discount rate dcf
lift price target
bottom line would continu buyer believ complet
turnaround busi focus drive expans
hybrid model corporate-own franchis clinic view perform
clinic level improv portfolio believ allow
acceler expans fund posit cash flow exist clinic believ
ceo peter holt implement highli effect strategi sinc appoint
juli leadership benefit transit turnaround
growth stori overal optimist growth potenti top
retail chain highli fragment rapidli grow chiropract market
addit corporate-own clinic april announc ad
clinic corporate-own portfolio first time sinc specif
bought exist franchis clinic locat san diego california cluster
clinic region posit acquir clinic oper success
expect compani initi focus clinic buyback expect
three addit could potenti open mani two greenfield well
shift strategi come exist corporate-own portfolio gener posit
ebitda drag overal profit prior two year
year launch success expect rate addit acceler
overal see major growth opportun current gener
roughli annual revenu per corporate-own clinic compar
profit report full-year adjust ebitda loss
signific narrow primarili driven
ebitda improv corporate-own clinic portfolio moreov new franchis
clinic seen better perform class reach break-even
averag nine month compar histor averag month believ
bode well begin open new corporate-own clinic
goal quickli effect drive profit
attract valuat current trade ev/revenu estim
compar peer averag new price target base
dcf analysi discount rate termin growth rate impli share
trade ev/revenu estim industri averag see
signific growth opportun compani highli fragment chiropract
click full note
expect competitor buy draa player tri
catch lead cloud data servic rais
pt
ep compound-annual-growth-rate guidanc underpin lead cloud data servic
drive share gain flattish on-premis data manag market
expect competitor buy draa player form basi
expect retain superior offer even competitor make
acquisit see manag run rate saa target end
aggress see page
believ deliv half saa commit viabl
respons price target increas see page
ep compound-annual-growth-rate guidanc underpin lead cloud data servic
drive share gain flattish on-premis data manag market
analyst day manag provid guidanc
paramet includ least ep compound-annual-growth-rate april see figur
page includ long-term guidanc target achiev software-as-a-servic
saa annual recur revenu end take
midpoint saa guidanc mid-singl digit overal revenu growth
guidanc triangul guidanc impli on-premis product revenu
increas compound-annual-growth-rate manag expect flattish on-premis data
storag market see figur page note on-premis product revenu
track increas y/i base prior check reason
upgrad manag assert analyst day believ
strong on-premis data manag share gain like futur share gain
result ntap uniqu hybrid cloud data manag capabl
expect competitor buy draa player form basi competit
cloud data servic capabl right view depict compani
cloud data servic capabl multi-lay product offer shown figur
page layer consist storag technolog layer whether
block file object-bas deliv either on-premis via public cloud
saa provid softwar data manag layer softwar
orchestr integr control layer data monitor optim
layer address layer suit storag product fuse data
layout softwar hardwar on-premis instanti in-beta cloud
volum saa instanti ontap data manag softwar
also fuse hardwar on-premis product cloud ontap
instanti netapp cloud control come greenqloud
technolog acquir august netapp cloud insight
come nativ cloud-bas oncommand insight version on-premis
version releas later note player public
cloud base monitor optim autom integr technolog
purchas notabl ntap technolog intern develop
except nativ cloud-bas storag technolog
data manag layer given took effect five year extract
ontap hardwar port public cloud player platform believ
player look acquir nativ cloud-bas data manag technolog
key target includ datto axcient infrascal start disast
recoveri servic draa player dell/emc look
protect legaci storag data manag busi
click full note
dilut capit lassa fever mer
inovio announc partnership cepi coalit epidem
prepared innov develop inovio dna-bas vaccin target
lassa fever mer middl east respiratori syndrom deal includ
support develop studi year period
compani current cash exclud capit cepi
addit bring non-dilut capit cepi award
valid inovio dna-bas vaccin infecti diseas platform
lassa mer virus-born diseas endem region
africa middl east high rate mortal dna-bas vaccin
rapidli induc neutral antibodi respons follow cell respons
lassa mer well diseas like ebola zika rapid
onset lethal short period time short time wait
cell inovio vaccin gener antibodi quickli ideal
diseas breaks-out gener virus-specif cell induc
conclus await data immun oncolog program
pivot data infecti diseas pipelin
continu provid catalyst stock non-dilut capit
offset develop cost expect data updat public
well potenti new partnership infecti diseas report
head year
mer vaccin phase studi subject receiv
regimen gener high titer bind antibodi
gener mer specif cell respons primat model mer
induc protect mer anim
lassa fever inovio collabor armi dr conni schmaljohn
chief scientist armi medic research institut infecti diseas
announc posit data dna-bas vaccin demonstr protect
non-human primat lethal dose lassa fever viru like ebola lassa viru
caus hemorrhag fever high mortal rate lassa data publish
journal human vaccin dna vaccin deliv
antibodi control viral diseas vaccin dmab cell
get much attent immun oncolog play key role infecti diseas
clear viral infect cell humor antibody-medi respons
import antibodi neutral free viru blood label viral
infect cell cell kill howev gener cell cell antibody-
produc cell take week month typic vaccin approach
lassa fever influenza may long though critic long-term
protect inovio dna-bas vaccin induc cell antibodi respons
rapidli easi deliveri system deploy pandem area
long term protect stop outbreak spread critic import
rapid respons therapeut like antibodi inovio vaccin
may ideal stockpil rapid deploy event outbreak
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
relat compani mention report
